De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Edwards Lifesciences Beheer
Beheer criteriumcontroles 3/4
De CEO Edwards Lifesciences' is Bernard Zovighian, benoemd in May2023, heeft een ambtstermijn van 1.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.87M, bestaande uit 7.6% salaris en 92.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.012% van de aandelen van het bedrijf, ter waarde $ 4.72M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 4.4 jaar.
Belangrijke informatie
Bernard Zovighian
Algemeen directeur
US$12.9m
Totale compensatie
| Percentage CEO-salaris | 7.6% |
| Dienstverband CEO | 1.4yrs |
| Eigendom CEO | 0.01% |
| Management gemiddelde ambtstermijn | 5.1yrs |
| Gemiddelde ambtstermijn bestuur | 4.4yrs |
Recente managementupdates
Recent updates
Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 30Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Jun 15Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed
Jun 12Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
May 31Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$13m | US$973k | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$1b |
| Dec 31 2022 | US$3m | US$642k | US$2b |
Compensatie versus markt: De totale vergoeding ($USD 12.87M ) Bernard } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).
Compensatie versus inkomsten: De vergoeding van Bernard is het afgelopen jaar met meer dan 20% gestegen.
CEO
Bernard Zovighian (56 yo)
1.4yrs
Tenure
US$12,869,020
Compensatie
Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$12.87m | 0.012% $ 4.7m | |
| Corporate VP & CFO | 10.8yrs | US$5.95m | 0.045% $ 17.9m | |
| Corporate Vice President of Strategy & Corporate Development | 8.7yrs | US$4.29m | 0.034% $ 13.5m | |
| Corporate VP and Group President of TAVR & Surgical Structural Heart | 1.8yrs | US$5.40m | 0.034% $ 13.3m | |
| Principal Accounting Officer | less than a year | geen gegevens | 0.00029% $ 114.4k | |
| Corporate VP of Advanced Technology & Chief Scientific Officer | 5.7yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Corporate VP & General Counsel | 5.1yrs | geen gegevens | geen gegevens | |
| Corporate Vice President of Public Affairs | 11.3yrs | geen gegevens | geen gegevens | |
| Corporate Vice President of Human Resources | 12.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Quality & Regulatory Compliance | 1.3yrs | geen gegevens | geen gegevens | |
| GM & Senior VP of Surgical Structural Heart | 1.2yrs | geen gegevens | 0.00021% $ 82.8k |
5.1yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van EW is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$12.87m | 0.012% $ 4.7m | |
| Independent Director | 9.7yrs | US$335.06k | 0.012% $ 4.7m | |
| Independent Director | 4.3yrs | US$329.97k | 0.0013% $ 505.0k | |
| Independent Director | 8.6yrs | US$335.06k | 0.012% $ 4.7m | |
| Independent Director | 8.3yrs | US$356.42k | 0.0045% $ 1.8m | |
| Independent Chairman | 9.9yrs | US$347.97k | 0.011% $ 4.5m | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 4.4yrs | US$334.97k | 0.0018% $ 722.0k |
4.4yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van EW wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).